AAAAAA

   
Results: 1-25 | 26-35
Results: 1-25/35
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ STOTER G VERWEIJ J NOOTER K
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Journal of chromatography B. Biomedical sciences and applications, 712(1-2), 1998, pp. 225-235
DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION
Authors: SPARREBOOM A DEBRUIJN P NOOTER K LOOS WJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION, Journal of chromatography B. Biomedical sciences and applications, 705(1), 1998, pp. 159-164
PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA NOOTER K LOOS WJ PORRO MG VERWEIJ J
Citation: A. Sparreboom et al., PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(8), 1998, pp. 1915-1919
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ BROUWER E VIGANO L LOCATELLI A DEVOS AI NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Clinical cancer research, 4(8), 1998, pp. 1937-1942
IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS
Authors: SPARREBOOM A DEJONGE MJA DEBRUIJN P BROUWER E NOOTER K LOOS WJ VANALPHEN RJ MATHIJSSEN RHJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS, Clinical cancer research, 4(11), 1998, pp. 2747-2754
PRECLINICAL PHARMACOKINETICS OF PACLITAXEL AND DOCETAXEL
Authors: SPARREBOOM A VANTELLINGEN O NOOIJEN WJ BEIJNEN JH
Citation: A. Sparreboom et al., PRECLINICAL PHARMACOKINETICS OF PACLITAXEL AND DOCETAXEL, Anti-cancer drugs, 9(1), 1998, pp. 1-17
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Annals of oncology, 9, 1998, pp. 219-219
LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION, Annals of oncology, 9, 1998, pp. 228-228
CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY, Annals of oncology, 9, 1998, pp. 229-229
PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: DEJONGE MJA PUNT CJA SPARREBOOM A LOOS WJ VANBEURDEN V PLANTING AST DALLAIRE B VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 243-243
PHASE-I TRIAL OF IRINOTECAN (CPT-11) COMBINED WITH CISPLATIN (C) GIVEN ONCE EVERY 3 WEEKS TO PATIENTS WITH SOLID TUMORS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST VANDERBURG MEL DEBOERDENNERT MM DEBRUYN P JACQUES C VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I TRIAL OF IRINOTECAN (CPT-11) COMBINED WITH CISPLATIN (C) GIVEN ONCE EVERY 3 WEEKS TO PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 259-259
ORAL TOPOTECAN (T) ON A DAILY X 5 SCHEDULE IN COMBINATION WITH INTRAVENOUS CISPLATIN (C) - A PHASE-I AND PHARMACOLOGICAL STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST BROUWER E VANDERBURG MEL HEARN S VERWEIJ J
Citation: Mja. Dejonge et al., ORAL TOPOTECAN (T) ON A DAILY X 5 SCHEDULE IN COMBINATION WITH INTRAVENOUS CISPLATIN (C) - A PHASE-I AND PHARMACOLOGICAL STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 264-264
A RAPID COLORIMETRIC DYE-BINDING MICROASSAY FOR QUANTITATION OF THE PACLITAXEL VEHICLE CREMOPHOR EL
Authors: SPARREBOOM A LOOS WJ BROUWER E NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., A RAPID COLORIMETRIC DYE-BINDING MICROASSAY FOR QUANTITATION OF THE PACLITAXEL VEHICLE CREMOPHOR EL, Annals of oncology, 9, 1998, pp. 503-503
CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN COMBINATION WITH GF120918, A POTENT INHIBITOR OF MDR1 P-GLYCOPROTEIN
Authors: SPARREBOOM A PLANTING AST JEWELL RC PAUL EM WISSEL PS DEBRUIJN P NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN COMBINATION WITH GF120918, A POTENT INHIBITOR OF MDR1 P-GLYCOPROTEIN, Annals of oncology, 9, 1998, pp. 550-550
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ VIGANO L LOCATELLI A NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Annals of oncology, 9, 1998, pp. 551-551
THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS - A REVIEW OF PRECLINICAL AND EARLY CLINICAL-STUDIES
Authors: DEJONGE MJA SPARREBOOM A VERWEIJ J
Citation: Mja. Dejonge et al., THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS - A REVIEW OF PRECLINICAL AND EARLY CLINICAL-STUDIES, Cancer treatment reviews, 24(3), 1998, pp. 205-220
LINEARIZED COLORIMETRIC ASSAY FOR CREMOPHOR EL - APPLICATION TO PHARMACOKINETICS AFTER 1-HOUR PACLITAXEL INFUSIONS
Authors: BROUWER E VERWEIJ J HAUNS B LOOS WJ NOOTER E MROSS K STOTER G SPARREBOOM A
Citation: E. Brouwer et al., LINEARIZED COLORIMETRIC ASSAY FOR CREMOPHOR EL - APPLICATION TO PHARMACOKINETICS AFTER 1-HOUR PACLITAXEL INFUSIONS, Analytical biochemistry (Print), 261(2), 1998, pp. 198-202
QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY
Authors: SPARREBOOM A LOOS WJ VERWEIJ J DEVOS AI VANDERBURG MEL STOTER G NOOTER K
Citation: A. Sparreboom et al., QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY, Analytical biochemistry, 255(2), 1998, pp. 171-175
DETERMINATION OF IRINOTECAN (CPT-11) AND ITS ACTIVE METABOLITE SN-38 IN HUMAN PLASMA BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
Authors: DEBRUIJN P VERWEIJ J LOOS WJ NOOTER K STOTER G SPARREBOOM A
Citation: P. Debruijn et al., DETERMINATION OF IRINOTECAN (CPT-11) AND ITS ACTIVE METABOLITE SN-38 IN HUMAN PLASMA BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION, Journal of chromatography B. Biomedical sciences and applications, 698(1-2), 1997, pp. 277-285
DETERMINATION OF THE LACTONE AND LACTONE PLUS CARBOXYLATE FORMS OF 9-AMINOCAMPTOTHECIN IN HUMAN PLASMA BY SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
Authors: LOOS WJ SPARREBOOM A VERWEIJ J NOOTER K STOTER G SCHELLENS JHM
Citation: Wj. Loos et al., DETERMINATION OF THE LACTONE AND LACTONE PLUS CARBOXYLATE FORMS OF 9-AMINOCAMPTOTHECIN IN HUMAN PLASMA BY SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION, Journal of chromatography B. Biomedical sciences and applications, 694(2), 1997, pp. 435-441
SENSITIVE DETERMINATION OF DOCETAXEL IN HUMAN PLASMA BY LIQUID-LIQUID-EXTRACTION AND REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
Authors: LOOS WJ VERWEIJ J NOOTER K STOTER G SPARREBOOM A
Citation: Wj. Loos et al., SENSITIVE DETERMINATION OF DOCETAXEL IN HUMAN PLASMA BY LIQUID-LIQUID-EXTRACTION AND REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical sciences and applications, 693(2), 1997, pp. 437-441
PHASE-I AND PHARMACOKINETIC STUDY OF XELODA(TM) (CAPECITABINE) IN COMBINATION WITH DOCETAXEL
Authors: VASEY PA PRONK L TWELVES C SPARREBOOM A WILSON P GORDON RJ OSTERWALDER B VERWEIJ J
Citation: Pa. Vasey et al., PHASE-I AND PHARMACOKINETIC STUDY OF XELODA(TM) (CAPECITABINE) IN COMBINATION WITH DOCETAXEL, European journal of cancer, 33, 1997, pp. 1113-1113
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF IRINOTECAN (CPT-11) AND CISPLATIN IN PATIENTS WITH SOLID TUMORS - PRELIMINARY-RESULTS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST VANDERBURG MEL DEBRUIJN P BROUWER E VANBEURDEN V VANDUIJN MR JACQUES C VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF IRINOTECAN (CPT-11) AND CISPLATIN IN PATIENTS WITH SOLID TUMORS - PRELIMINARY-RESULTS, European journal of cancer, 33, 1997, pp. 1134-1134
DIFFERENTIAL MODULATION OF CISPLATIN ACCUMULATION IN LEUKOCYTES AND TUMOR-CELL LINES BY THE PACLITAXEL VEHICLE CREMOPHOR EL
Authors: DEVOS AI NOOTER K VERWEIJ J LOOS WL BROUWER E DEBRUIJN P RUIJGROK EJ VANDERBURG MEL STOTER G SPARREBOOM A
Citation: Ai. Devos et al., DIFFERENTIAL MODULATION OF CISPLATIN ACCUMULATION IN LEUKOCYTES AND TUMOR-CELL LINES BY THE PACLITAXEL VEHICLE CREMOPHOR EL, Annals of oncology, 8(11), 1997, pp. 1145-1150
LIMITED ORAL BIOAVAILABILITY AND ACTIVE EPITHELIAL EXCRETION OF PACLITAXEL (TAXOL) CAUSED BY P-GLYCOPROTEIN IN THE INTESTINE
Authors: SPARREBOOM A VANASPEREN J MAYER U SCHINKEL AH SMIT JW MEIJER DKF BORST P NOOIJEN WJ BEIJNEN JH VANTELLINGEN O
Citation: A. Sparreboom et al., LIMITED ORAL BIOAVAILABILITY AND ACTIVE EPITHELIAL EXCRETION OF PACLITAXEL (TAXOL) CAUSED BY P-GLYCOPROTEIN IN THE INTESTINE, Proceedings of the National Academy of Sciences of the United Statesof America, 94(5), 1997, pp. 2031-2035
Risultati: 1-25 | 26-35